• Molecular NameEnalaprilat
  • SynonymEnalapril Maleate; Enalaprila [INN-Spanish]; Enalapril; Enalaprilum [INN-Latin]
  • Weight376.453
  • Drugbank_IDN/A
  • ACS_NO76420-72-9, 84680-54-6
  • Show 3D model
  • LogP (experiment)-0.74
  • LogP (predicted, AB/LogP v2.0)0.54
  • pkaN/A
  • LogD (pH=7, predicted)-2.73
  • Solubility (experiment)Slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)0.42
  • LogSw (predicted, AB/LogsW2.0)14.61
  • Sw (mg/ml) (predicted, ACD/Labs)36.88
  • No.of HBond Donors2
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds10
  • TPSA95.94
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyN/A
  • Absorption_value10.0
  • Absorption (description)Enalaprilat is poorly absorbed following oral administration and is used as intravenous formulation only.
  • Caco_2-5.64
  • BioavailabilityN/A
  • Protein binding50.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmExcretion of enalaprilat is primarily renal with more than 90 percent of an administered dose recovered in the urine as unchanged drug within 24 hours.
  • Half life38 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most frequent clinically significant adverse experience was hypotension, congestive heart failure, coronary artery disease, headache, nausea.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A